Quince Therapeutics (NASDAQ:QNCX) Coverage Initiated at Rodman & Renshaw

Research analysts at Rodman & Renshaw initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note issued to investors on Tuesday, Benzinga reports. The firm set a “buy” rating and a $11.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I raised Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd.

Quince Therapeutics Trading Up 11.0 %

QNCX opened at $1.31 on Tuesday. The firm has a market cap of $56.61 million, a price-to-earnings ratio of -1.72 and a beta of 0.86. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $1.79. The business’s 50 day moving average is $0.79 and its two-hundred day moving average is $0.80. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.29.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Insider Activity at Quince Therapeutics

In other Quince Therapeutics news, CEO Dirk Thye acquired 77,500 shares of the business’s stock in a transaction on Thursday, August 29th. The stock was purchased at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the transaction, the chief executive officer now owns 766,941 shares of the company’s stock, valued at $529,189.29. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Dirk Thye bought 77,500 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was bought at an average cost of $0.69 per share, with a total value of $53,475.00. Following the completion of the acquisition, the chief executive officer now owns 766,941 shares in the company, valued at approximately $529,189.29. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Charles S. Ryan acquired 48,387 shares of Quince Therapeutics stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average cost of $0.65 per share, with a total value of $31,451.55. Following the completion of the acquisition, the president now owns 122,461 shares of the company’s stock, valued at $79,599.65. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 158,887 shares of company stock worth $105,609 over the last three months. 16.80% of the stock is currently owned by corporate insiders.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.